Eleven BASF Sites Awarded GMP Certification for Cosmetic Ingredients
News Apr 02, 2014
BASF has been awarded the Good Manufacturing Practice (GMP) certification for cosmetic ingredients according to the European Federation for Cosmetic Ingredients (EFfCI).
The certification applies to eleven BASF sites across all regions producing ingredients for the personal care industry. It confirms that the sites comply with strict guidelines on product quality and industry hygiene during the manufacturing process.
In the long term, BASF aims to achieve GMP certifications for all relevant cosmetic ingredients production sites worldwide.
“The cosmetic industry has been taking note of consumers’ increasing demands in terms of product quality and safety. This is why our customers expect our products to meet the highest standards. EFfCI’s GMP certification proves that we maintain these standards all over the world,” said Jan-Peter Sander, Senior Vice President Personal Care Europe.
The GMP guidelines for cosmetics are updated regularly to take into account the latest developments within the cosmetics industry, and were last reworked in 2012 to incorporate quality risk management and other contemporary principles.
EFfCI is a European trade association and was set up in 2000 to represent the collective interests of more than 100 cosmetic ingredient companies in Europe.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE